News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
103 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37190)
2018 (39122)
2019 (51337)
2020 (57666)
2021 (58724)
2022 (53929)
2023 (42567)
2024 (37443)
2025 (33092)
2026 (3716)
Month
January (3218)
February (3391)
March (3462)
April (3660)
May (4506)
June (2887)
July (2192)
August (2499)
September (2721)
October (3233)
November (3383)
December (2291)
Day
1 (168)
2 (144)
3 (119)
4 (78)
7 (116)
8 (161)
9 (155)
10 (156)
11 (59)
14 (75)
15 (187)
16 (113)
17 (182)
18 (78)
20 (6)
21 (130)
22 (103)
23 (158)
24 (166)
25 (146)
28 (152)
29 (195)
30 (196)
31 (190)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
7
8
9
10
11
14
15
16
17
18
20
21
22
23
24
25
28
29
30
31
Complete response letters
FDA Rejects Camurus’ Rare Hormonal Disorder Treatment Due to Manufacturing Problems
The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its extended-release subcutaneous formulation of octreotide, which would allow more convenient once-monthly dosing for patients with acromegaly.
October 22, 2024
·
2 min read
·
Tristan Manalac
Employer Resources
Report: Employer Branding: What Matters to Life Sciences Candidates
October 22, 2024
·
1 min read
·
BioSpace Insights
Legal
Lilly Ups Legal Offensive Against Tirzepatide Copycats as FDA Mulls Shortage Status
Monday’s lawsuits from Eli Lilly are the first to be filed by the pharma since the regulator officially removed tirzepatide from its drug shortage database earlier this month.
October 22, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
October 22, 2024
·
1 min read
·
Annalee Armstrong
Leadership
Leadership Lab: 10 Ways Executives Can Stay Visible, Valuable Between Jobs
For biopharma executives who are between roles, navigating the transitionary time can be challenging. However, they can remain visible and valuable so they’re ready to seize their next big opportunity.
October 22, 2024
·
5 min read
·
Michael Pietrack
Manufacturing
Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs
Nucleus RadioPharma’s two sites are meant to help address the industry’s lack of manufacturing and development capabilities, as well as geographic limitations associated with the short half-life of many radioactive components.
October 22, 2024
·
2 min read
·
Tristan Manalac
Business
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its rivals, according to
The Wall Street Journal
.
October 22, 2024
·
2 min read
·
Tristan Manalac
Press Releases
GRI Bio Announces Exercise of Warrants
October 22, 2024
·
7 min read
Press Releases
Seamless Therapeutics to Present New Data at ESGCT Demonstrating its Ability to Reprogram Large Serine Recombinases to Specific Target Sites in the Human Genome
October 22, 2024
·
4 min read
Press Releases
BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL
October 22, 2024
·
4 min read
1 of 11
Next